CapyFin

Calendar Reports

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

NewAmsterdam Pharma Fiscal Q1 2024 Earnings Report - CapyFin

NewAmsterdam Pharma

NAMS · NASDAQ🇳🇱

Overview Earnings

Dividends Seasonality Metrics

Q3 2025 +4.33%Q2 2025 +8.75%Q1 2025 +1.25%Q1 2026 +1.25%Q4 2024 +10.23%Q3 2023 +18.22%Q3 2024 +18.22%Q2 2024 +4.19%Q1 2024 -9.64%Q2 2023 -5.74%Q4 2023 -5.74%Q1 2023 +0.28%Q4 2021 +2.11%Q4 2022 +2.11%Q3 2022 -0.10%Q2 2022 +0.10%Q1 2022 0.00%Q3 2021 -0.31%Q2 2021 +0.20%Q1 2021 +0.10%Q4 2020 Q3 2020 Q2 2020 Q1 2020

Mar 31, 2024

•

Mar 31, 2024

NewAmsterdam Pharma Q1 2024 Earnings Report

Previous year: $8.63M

Previous year: -$0.51

Research and Development Expenses

Selling, General and Administrative Expenses

Total Operating Expenses

Previous year: $7.96M

Cash and Equivalents

NewAmsterdam Pharma

Unlock previous datapoints

NewAmsterdam Pharma

Unlock previous datapoints

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

View NewAmsterdam Pharma